Item 1.01 Entry into a Material Definitive Agreement.
On December 9, 2021, Oncotelic Therapeutics, Inc.
(the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire
Global Opportunities Fund, LLC (the (“Holder”), pursuant to which the Company issued a convertible promissory note
in the aggregate principal amount of $0.25 million (the “Note”). On December 12, 2021, the Company entered
into a Securities Purchase Agreement (the “Blue Lake Purchase Agreement”) with Blue Lake Partners, LLC (“Blue
Lake”), pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $0.25 million
(the “Blue Lake Note”). Further on December 15, 2021, the Company entered into a Securities Purchase Agreement
(the “Fourth Man Purchase Agreement”, and collectively with the Purchase Agreement and the Blue Lake Purchase Agreement,
the “Purchase Agreements”), with Fourth Man, LLC (“Fourth Man”), pursuant to which the Company
issued a convertible promissory note in the aggregate principal amount of $0.25 million (the ‘Fourth Man Note”, and
collectively with the Note and the Blue Lake Note, the “Notes”). The Notes are convertible into shares of the
Company’s common stock, par value $0.01 per share (“Common Stock”).
The Purchase Agreements and the Notes were entered
into as part of a convertible note financing round with aggregate gross proceeds to the Company of up to $1.25 million (the “Financing”),
undertaken by the Company pursuant to that certain Finder’s Fee Agreement between the Company and JH Darbie & Co., Inc. (“JH
Darbie”), dated October 26, 2021 (the “Agreement”). Pursuant to the Agreement, JH Darbie will be entitled
to a finder’s fee of: (a) 10% of the gross proceeds received by the Company in cash; and (b) warrants equal 10% warrant coverage
of the amount raised, with a purchase price equal to the Conversion Price, with such warrants to expire five years from the date of issuance.
The issuance and sale of the Notes on December 9, 2021, December 12, 2021 and December 15 2021, respectively, represented the
third, fourth and fifth tranches of the Financing, totaling a gross of $0.75 million, for an aggregate gross total
of $1.25 million across the five tranches. The Purchase Agreements and the Notes contain identical terms to the securities
purchase agreements (and promissory notes issued thereunder), to Talos Victory Fund, LLC on November 24, 2021 and Mast Hill Fund, LP
on November 30, 2021 (the “Prior Issuances”), except with reference to the name of the holders, the use of proceeds,
which include repayment of certain debt, general corporate expenses and payroll, as applicable, and the law governing the terms of the
Prior Issuances. The Prior Issuances were previously reported on our Current Report on Form 8-K filed with the Securities and Exchange
Commission (“SEC”) on December 1, 2021.
The
Notes carry an interest rate of 12% per annum and matures on the earlier of (a) the one-year anniversary of the date of the Purchase
Agreements, or (b) the acceleration of the maturity of the Notes by the applicable holder upon occurrence of an Event of Default (as
defined below). The Notes contain a voluntary conversion mechanism whereby the applicable holder may convert the outstanding principal
and accrued interest under the terms of the Notes into shares of Common Stock (the “Conversion Shares”), at a fixed
price of $0.07 per share (the “Conversion Price”), subject to adjustments upon the occurrence of certain corporate
events. Prepayment of the Notes may be made at any time upon three trading days’ prior written notice to the respective holder,
by payment of the then outstanding principal amount plus accrued and unpaid interest and reimbursement of such holder’s administrative
fees. The Notes contains customary events of default (each an “Event of Default”). If an Event of Default occurs,
at the respective holder’s election, the outstanding principal amount of the Notes, plus accrued but unpaid interest, will become
immediately due and payable in cash. The Purchase Agreements require the Company to use the proceeds for general working capital, and
not for (i) the repayment of any indebtedness owed to officers, directors or employees of the Company or their affiliates, (iii) any
loan to or investment in any other corporation, partnership, enterprise or other person (except in connection with the Company’s
currently existing operations), (iv) any loan, credit, or advance to any officers, directors, employees, or affiliates of the Company,
or (v) in violation or contravention of any applicable law, rule or regulation.
The
issuance of the Notes are exempt from the registration requirements of the Securities Act of 1933, as amended (“Securities Act”),
in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act. The shares of Common Stock issuable upon conversion
of the Notes have not been registered under the Securities Act or any other applicable securities laws, and unless so registered, may
not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act.
The
foregoing descriptions of the Purchase Agreements and the Notes are qualified in their entirety by reference to the full text of the
form of such agreements, copies of which were attached as Exhibit 10.1 and 10.2, respectively, and the Agreement, attached as Exhibit
10.3, with our Current Report on form 8-K filed with the SEC on December 1, 2021 and each of which is incorporated herein in its entirety
by reference.
Item
8.01
The
Company fully repaid the May 2021 and June 2021 Geneva Notes of $203,750 $103,750, respectively, including interest and prepayment penalty
in full, and in compliance with the Prior Issuances.